COPCOV Investigators
A global network of scientific, medical and research trial collaborators works together on COPCOV, the MORU-led, Oxford-supported study to test if hydroxychloroquine or chloroquine can prevent COVID-19.
As vaccines begin to roll out, finding drugs that prevent COVID-19 is more important than ever: It may be mid-2022 before there are enough COVID-19 vaccines for the 7.5 billion people on this planet. Scientifically proving that hydroxychloroquine provides even a small health benefit could save thousands of lives before vaccines become widely available, and COVID-19 brought under control. Understanding whether these drugs can effectively prevent COVID-19 infection would also support global preparedness for future potential emerging viral threats.
COPCOV has recruited participants from sites in Benin, Côte d’Ivoire, Indonesia, Kenya, Mali, Nepal, Pakistan, Zambia, Thailand, Niger and the UK. Preliminary study results are expected early Q2 2022.
Principal Investigators
Investigators
-
Nicholas Day
Professor of Tropical Medicine
-
Bob Taylor
Professor of Tropical Medicine
-
Elizabeth Ashley
Professor of Tropical Medicine
-
Paul Turner
Professor of Paediatric Microbiology
-
Arjun Chandna
Research Physician
-
Guy Thwaites
Professor of Infectious Diseases
-
Martin Llewelyn
Professor in Infectious Diseases
-
Amanda Adler
Director, Diabetes Trials Unit
-
Phaik Yeong Cheah
Professor of Global Health
-
Arjen Dondorp
Professor of Tropical Medicine
-
Mayfong Mayxay
Vice-President of the Lao University of Health Sciences, Ministry of Health
-
James Callery
Research Physician
-
Piero Olliaro
Professor of Poverty Related Infectious Diseases
-
Sophie Yacoub
Research Group Leader
Trial Researchers
-
Mavuto Mukaka
Professor of Medical Statistics and Epidemiology
-
Maneerat Ekkapongpisit
iTPA Manager